Glaucoma market will see growth due to pipeline products, says GlobalData

The latest report from data and analytics company, GlobalData, has revealed that the glaucoma market is expected to grow to $3.8 billion in 2026 as a result of the launch of pipeline products.

‘PharmaPoint: Glaucoma’ predicts that five products, currently in late-stage pipeline, will enter the market during the forecast period. These five products include Santen’s drug DE-117m Aerie’s fixed-dose combination therapy (Roclatan), two sustained-release implants and a drug with an undisclosed MOA.

“The late-stage pipeline drugs are set to have a significant impact on the glaucoma market, and be a key driver of growth throughout the forecast period,” explained Thomas Moore, healthcare analyst at GlobalData. “GlobalData forecasts that two pipeline products, Aerie’s Roclatan and Allergan’s Bimatoprost SR, will become the most successful drugs in the glaucoma market, with sales of $631.9M and $609.5M, respectively. Overall, GlobalData predicts that drugs that launch during the forecast period will account for 41% of the global glaucoma market in 2026.”

There has been a shifting trend of pharma companies to focus on developing new drugs for glaucoma since 2014, according to GlobalData, which anticipates this trend to continue throughout its forecast period. With launches, such as Kowa’s Glanatec (ripasudil) — launched in Japan in 2014 — and recent approvals such as that of Valeant’s Vyzulta (latanoprostene bunod) and Aerie Pharmaceuticals’ Rhopressa (netarsudil), new classes of glaucoma drugs are becoming available.

“Some pharmaceutical companies have opted to continue the established strategy of reformulating existing drugs for glaucoma to provide added value,” Moore continued. “In particular, there are two late-stage pipeline products, Ocular Therapeutix’s OTX-TP and Allergan’s Bimatoprost SR, which contain established prostaglandin analogues reformulated into an SR implant. These products are set to address poor patient adherence in glaucoma patients, and are expected to have a significant impact on the glaucoma market.”